Author details

Full Name

Priscilla K Brastianos

Affiliation

ORCID

Career Start Year

2003

Papers

186

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37622466	Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.	Pigment Cell Melanoma Res	2024
38070147	Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.	Neuro Oncol	2024
36847897	Journal of Neuro-Oncology, Meningioma issue.		2023
36181606	Emerging systemic treatment options in meningioma.	J Neurooncol	2023
36288512	Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations.	J Clin Oncol	2023
37693537	Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy.	bioRxiv	2023
37611074	CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.		2023
36912773	Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer.	Mol Cancer Ther	2023
37210133	Novel Systemic Approaches for the Management of Meningiomas: Immunotherapy and Targeted Therapies.		2023
37085569	Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.	Nat Rev Clin Oncol	2023
37268724	Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.	Nat Med	2023
36705597	Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.	Clin Cancer Res	2023
36809604	Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability.		2023
37437144	BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.	N Engl J Med	2023
37432630	Novel Medical Therapies in Meningiomas.		2023
37358877	Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.		2023
36990614	Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference.	Lancet Oncol	2023
37527941	Association of <i>MTHFR</i> Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens.	Neurology	2023
37527676	Introduction. Update on brain metastases.	Neurosurg Focus	2023
37524847	A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.		2023
37491527	Leveraging translational insights toward precision medicine approaches for brain metastases.		2023
37541280	National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.	Lancet Oncol	2023
34932393	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.	J Clin Oncol	2022
35912544	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.	Pigment Cell Melanoma Res	2022
35394521	Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity.	Cancer Discovery	2022
35708940	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.	CA Cancer J Clin	2022
35522917	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.	American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting	2022
35706413	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.	Cancer Immunol Res	2022
35762249	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.	Neuro Oncol	2022
35943573	Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord.	Acta Neuropathologica	2022
35561283	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline.	J Clin Oncol	2022
36338769	Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis.	Front Oncol	2022
35404402	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.	Clin Cancer Res	2022
34799864	Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.	Neuropathol Appl Neurobiol	2022
34791428	Consensus core clinical data elements for meningiomas (v2021.1).	Neuro Oncol	2022
35289329	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.	Nat Commun	2022
34732332	Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice.	Brain Research	2022
34711458	Central Nervous System Metastases.	Hematol Oncol Clin North Am	2022
35100424	Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.	Neuro-Oncology	2022
34642316	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.	Nat Commun	2021
33592174	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.	Cell	2021
33967180	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.	Neurol Med Chir (Tokyo)	2021
34014298	Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.	JAMA Oncol	2021
34281989	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.	J Immunother Cancer	2021
33735913	A rapid genotyping panel for detection of primary central nervous system lymphoma.	Blood	2021
33941922	Evolution of delayed resistance to immunotherapy in a melanoma responder.	Nat Med	2021
34207653	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.	Cancers	2021
33611710	Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.	J Neurooncol	2021
33658202	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.	Sci Adv	2021
33547796	A broad perspective on evaluating bias in the neuro-oncology workplace.	Neuro Oncol	2021